KLCM Advisors Inc. Sells 97,485 Shares of Organon & Co. $OGN

KLCM Advisors Inc. cut its stake in shares of Organon & Co. (NYSE:OGN) by 8.0% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,122,830 shares of the company’s stock after selling 97,485 shares during the quarter. Organon & Co. accounts for about 1.2% of KLCM Advisors Inc.’s portfolio, making the stock its 24th largest position. KLCM Advisors Inc. owned about 0.43% of Organon & Co. worth $11,992,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also added to or reduced their stakes in OGN. BNP Paribas Financial Markets grew its stake in shares of Organon & Co. by 335.8% during the third quarter. BNP Paribas Financial Markets now owns 957,667 shares of the company’s stock worth $10,228,000 after buying an additional 737,935 shares during the last quarter. Franklin Resources Inc. grew its position in Organon & Co. by 2.5% during the 3rd quarter. Franklin Resources Inc. now owns 414,588 shares of the company’s stock worth $4,428,000 after acquiring an additional 10,030 shares during the last quarter. Quadrant Capital Group LLC bought a new position in Organon & Co. in the third quarter valued at about $116,000. Vestcor Inc boosted its stake in shares of Organon & Co. by 113.9% during the third quarter. Vestcor Inc now owns 41,888 shares of the company’s stock valued at $447,000 after purchasing an additional 22,307 shares in the last quarter. Finally, Swiss National Bank boosted its stake in shares of Organon & Co. by 2.3% during the third quarter. Swiss National Bank now owns 504,175 shares of the company’s stock valued at $5,385,000 after purchasing an additional 11,300 shares in the last quarter. 77.43% of the stock is currently owned by institutional investors and hedge funds.

Organon & Co. Stock Performance

NYSE:OGN opened at $6.41 on Thursday. The company has a debt-to-equity ratio of 11.47, a quick ratio of 1.23 and a current ratio of 1.82. Organon & Co. has a fifty-two week low of $6.18 and a fifty-two week high of $15.88. The company has a 50 day simple moving average of $7.93 and a two-hundred day simple moving average of $8.32. The company has a market capitalization of $1.67 billion, a PE ratio of 9.02, a P/E/G ratio of 0.60 and a beta of 0.60.

Organon & Co. (NYSE:OGN) last issued its quarterly earnings results on Thursday, February 12th. The company reported $0.63 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.73 by ($0.10). Organon & Co. had a return on equity of 122.01% and a net margin of 3.01%.The firm had revenue of $1.51 billion during the quarter, compared to analyst estimates of $1.52 billion. During the same quarter last year, the firm posted $0.90 EPS. The firm’s revenue for the quarter was down 5.3% on a year-over-year basis. Research analysts anticipate that Organon & Co. will post 3.68 earnings per share for the current year.

Organon & Co. Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, March 12th. Shareholders of record on Monday, February 23rd will be issued a dividend of $0.02 per share. This represents a $0.08 dividend on an annualized basis and a yield of 1.2%. The ex-dividend date is Monday, February 23rd. Organon & Co.’s dividend payout ratio (DPR) is presently 11.27%.

Analyst Ratings Changes

OGN has been the subject of several recent research reports. Wall Street Zen downgraded Organon & Co. from a “buy” rating to a “hold” rating in a research note on Saturday, January 31st. Zacks Research cut shares of Organon & Co. from a “hold” rating to a “strong sell” rating in a research note on Thursday, January 29th. Finally, Barclays increased their price objective on Organon & Co. from $7.50 to $8.00 and gave the company an “underweight” rating in a report on Tuesday, February 24th. One investment analyst has rated the stock with a Strong Buy rating, one has issued a Hold rating and five have issued a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Reduce” and a consensus target price of $8.50.

About Organon & Co.

Organon & Co is a global healthcare company that was established as an independent, publicly traded entity following its spin-off from Merck & Co in June 2021. Headquartered in Jersey City, New Jersey, Organon focuses on delivering therapeutic solutions across women’s health, biosimilars, and established brands. The company’s creation reflected a strategic effort to concentrate on specialty pharmaceuticals and legacy products with proven patient impact.

In women’s health, Organon provides a broad portfolio of products addressing reproductive and gynecological conditions, including fertility treatments, contraception, and hormone replacement therapies.